Table 2.
Markers of cardiovascular risk (52-week evaluable population)
| Markers of cardiovascular risk | |||
|---|---|---|---|
| Exenatide once-weekly → exenatide once-weekly n = 103 | Sitagliptin → exenatide once-weekly n = 116 | Pioglitazone → exenatide once-weekly n = 100 | |
| ACR (baseline) | 15.31 ± 2.37 | 11.46 ± 1.27 | 13.23 ± 1.92 |
| Δ weeks 26–52 | −19% (−31 to −5)* | −14% (−26 to 0) | −12% (−25 to 4) |
| Δ weeks 0–52 | −34% (−45 to −20)* | −18% (−31 to −3)* | −23% (−36 to −7)* |
| BNP (baseline; pg/ml) | 9.66 ± 1.00 | 11.69 ± 1.03 | 9.60 ± 0.84 |
| Δ weeks 26–52 | −10% (−23 to 6) | −16% (−27 to −3)* | −26% (−37 to −14)* |
| Δ weeks 0–52 | −18% (−31 to −3)* | −15% (−28 to −1)* | −13% (−26 to 3) |
| hsCRP (baseline; mg/l) | 2.50 ± 0.24 | 2.35 ± 0.18 | 2.33 ± 0.24 |
| Δ weeks 26–52 | −2% (−15 to 12) | −8% (−20 to 5) | 37% (19 to 58)* |
| Δ weeks 0–52 | −25% (−35 to −13)* | −17% (−27 to −4)* | −5% (−18 to 11) |
| PAI-1 (baseline; ng/ml) | 39.14 ± 2.29 | 32.97 ± 1.71 | 36.18 ± 1.95 |
| Δ weeks 26–52 | 16% (4 to 30)* | −3% (−12 to 8) | 27% (14 to 42)* |
| Δ weeks 0–52 | 4% (−8 to 16) | −8% (−18 to 2) | 12% (0 to 25) |
Baseline data are geometric mean ± se. Geometric least square mean % change (95% CI) for change from baseline or week 26.
*
P < 0.05.
Δ Change from previous value
ACR, urinary albumin/creatinine ratio; BNP, B-type natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor 1.